The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지

Selective Cytotoxicity of Novel Platinum(II) Coordination Complexes on Human Bladder Cancer Cell-Lines and Normal Kidney Cells

  • Kim, Jung-Tae (Department of Pharmacochemistry, College of Pharmacy, Kyung Hee University) ;
  • Rho, Young-Soo (Department of Pharmacochemistry, College of Pharmacy, Kyung Hee University) ;
  • Jung, Jee-Chang (Department of Pharmacology, School of Medicine, Kyung Hee University)
  • Published : 2003.04.21
Download PDF
⟨ Previous Next ⟩

Abstract

Cisplatin is often effective in cancer treatment, but its clinical use is limited because of its nephrotoxicity. We have synthesized new platinum(II) coordination complexes (PC-1 & PC-2) containing trans-${\iota}$ and cis-1,2-diaminocyclohexane (DACH) as carrier ligands and L-3 -phenyllactic acid (PLA) as a leaving group with the aim of reducing nephrotoxicity but maintaining its anticancer activity. In this study, new platinum(II) complex compounds were evaluated for selective cytotoxicity on cancer cell-lines and normal kidney cells. The new platinum complexes have demonstrated high efficacy in the cytotoxicity against human bladder carcinoma cell-lines (T-24/HT-1376). The cytotoxicity of these compounds against rabbit proximal renal tubular cells and human renal cortical tissues, was determined by MTT assay, the [3H]-thymidine uptake and glucose consumption test, and found to be quite less than those of cisplatin. Based on our results, these novel platinum compounds appear to be valuable lead compounds with high efficacy and low nephrotoxicity.

Keywords

References

  1. Burchenal JH, Kalaher K, Dew K, Lokys L. Rationale for development of platinum analogs. Cancer Treat Rep 63: 1493－1409, 1979
  2. Burchenal JH, Kalaher K, O'Toole T, Chisholm J. Lack of crossresistance between certain platinum coordination compounds in mouse leukemia. Cancer Rep 37: 3455－3457, 1977
  3. Calvert AH, Harland SJ, Newell DL, Harrap KP. Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev 12: 51－57, 1985 https://doi.org/10.1016/0305-7372(85)90018-0
  4. Chang SG, Chai SE, Kim ES, Yoon C, et al. The measurement of glucose consumption in histoculture to determine effects of doxorubicin and cisplatinum on gastric carcinoma. Anticancer Res 13: 1303－1310, 1993
  5. Chang SG, Lee JH, Hong DH, Lee HL, Chai SE, Hoffman RM. Comparison of glucose-consumption and thymidine-incorporation endpoints in histocultured human superficial bladder tumor. Anticancer Res 14: 77, 1994
  6. Chang SG, Toth K, Black JD, Slocum HK, Perrepato SD, Huben RP, Restum YM. Growth of human renal cortical tissues on collagen gel. In Vitro Cell Dev Biol 28A: 128－135, 1992
  7. Chung SD, Alavi N, Livingston D, Hiller S, Taub M. Characterization of primary rabbit kidney cultures that express proximal tubule functions in a hormonally defined medium. J Cell Biol 95: 118, 1982 https://doi.org/10.1083/jcb.95.1.118
  8. Clear MJ, Hoeschele JD. Antitumor platinum compound: relationship between structure and activity. Platinum Material Review 17: 2－10, 1973
  9. Connor TA, Jones, M, Ross WCJ. New platinum complexes with antitumor activity. Chem Bio Interact 5 415－420, 1972 https://doi.org/10.1016/0009-2797(72)90078-6
  10. Cook WF, Pickering GW. A rapid method for separating glomeruli from rabbit kidney. Nature 182: 1103－1104, 1958 https://doi.org/10.1038/1821103a0
  11. Cvitkovic E, Spaulding J, Bethune V. Improvement of cisdiaminedichloroplatinum (NSC-119875) : Therapeutic index in and animal model. Cancer 39: 1357, 1977 https://doi.org/10.1002/1097-0142(197704)39:4<1357::AID-CNCR2820390402>3.0.CO;2-C
  12. Daley-Yates PT, McBien DCH. Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxicity nephrotoxicity and antitumor activity of cisplatin. Biochem Pharmacol 33: 3063, 1984 https://doi.org/10.1016/0006-2952(84)90610-5
  13. Daley-Yates PT, McBrien DCH. The inhibition of renal ATPase by cisplatin and some biotransformation products. Chem Biol Interact 40: 325, 1982 https://doi.org/10.1016/0009-2797(82)90155-7
  14. Dobyan DC, Levi J, Jacobs C. Mechanism of cisplatinum nephrotoxicity. J Pharmacol Exp Ther 213(3): 515－556, 1980
  15. Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Inten Med 87: 293, 1977 https://doi.org/10.7326/0003-4819-87-3-293
  16. Einhorn LH. Treatment of testicular cancer: A new and improved model. J Clin Oncol 8: 1777－1781, 1990 https://doi.org/10.1200/JCO.1990.8.11.1777
  17. Gale GR, Walker EM, Atkins LM. Antileukemic properties of dichloro (1,2 diaminocyclohexane) platinum(II). Res Commum Chem Pathol Pharmacol 7: 529－533, 1974
  18. Groth S, Nielson H, Sorensen JB, Christensen AB, Pedeersen AG, Rorth M. Acute and long-term nephrotoxicity of cis-platinum in man. Cancer Chemother Pharmacol 17: 191, 1986 https://doi.org/10.1007/BF00306754
  19. Hill JM, Loeb E, MacLellan A. Clinical studies of platinum coordination compounds in the treatment of various malignant disease. Cancer Chemother Rep 59: 647, 1975
  20. Hoffman RM. To do tissue culture in two or three dimension? That is the question. Stem cell 11: 105－111, 1993 https://doi.org/10.1002/stem.5530110205
  21. Inagaki K, Kidani Y. Differences in binding of (1,2-diaminocyclohexane) platinum(II) isomers with d (GPG). Inorg Chem 25: 1－8, 1986 https://doi.org/10.1021/ic00221a001
  22. Jones MM, Basinger MA, Craft WD. Control of some aspects of cis-platinum nephrotoxicity. Arch Toxicol 59: 167－171, 1986 https://doi.org/10.1007/BF00316327
  23. Jones MM, Beaty JA. Rate of displacement of guanosine by cyanide from cis-diamminebis (guanosine) platinum(II) chloride determined by using [13C]-NMR spectroscopy. Inorg Chem 30: 1584, 1991 https://doi.org/10.1021/ic00007a030
  24. Jung JC, Kim YK, Park SJ, Chang SG, Lee KT, Baek MS, Park JJ, Rho YS. In vitro cytotoxicity of normal platinum(II) coordination complexes containing diaminocyclohexane and diphenylphosphine. Korean J Physiol Pharmacol 2: 395－401, 1998
  25. Jung JC, Kim YK, Park SJ, Chang SG, Lee KT, Rho YS. Selective cytotoxicity cell lines and normal kidney cells. Korean J Physiol Pharmacol 3: 283－291, 1999
  26. Kelsen DP, Scher H, Alcock N. Phases-I clinical trial and pharmacokinetics of 4'-carboxyphthalato (1,2-diaminocyclohexane) platinum(II). Cancer Res 42: 4831－4835, 1982
  27. Kiani Y. Development of antitumor platinum complexes: Yakugaku Zassshi 105: 909－914, 1985
  28. Kizu R, Higashi SY, Miyazaki M. Pharmacokinetics of (IR, 2Rdiaminocyclohexane) oxalato-platinum(II) in comparison with cisplatin following a single intravenous injection in rabbits. Cancer Chemother Pharmacol 31: 475－480, 1993 https://doi.org/10.1007/BF00685038
  29. Krakoff IH. Nephrotoxicity of cis-diamminedichloroplatinum(II). Cancer Treat Rep 63: 1523－1529, 1979
  30. Leighton J. A sponge matrix method for tissue culture. Formation of organized aggregations of cells in vitro. J Natl Cancer Inst 12: 545－561, 1951
  31. Lim MC, Martin RB. The nature of cis-amine Pd(II) and antitumor cis-amine Pt(II) complexes in aqueous solutions. J Inorg Nucl Chem(38): 1911, 1976 https://doi.org/10.1016/0022-1902(76)80121-2
  32. Littert CL. Alterations in the toxicity of cis-dichlorodiamineplatinum (II) and in tissue localization in the vehicle of administration. Toxicol Appl Pharmacol 61: 99－104, 1981 https://doi.org/10.1016/0041-008X(81)90011-9
  33. Madias NE, Harrington JT. Platinum nephrotoxicity. Am J Med 65: 307－314, 1978 https://doi.org/10.1016/0002-9343(78)90825-2
  34. Maijer S, Mulder LH, Sleijifer DT, Schraffordt KH. Nephrotoxicity of cisplatinum during remission-induction and maintenance chemotherapy of testicular carcinoma. Cancer Chemother Pharmacol 8: 27－30, 1982 https://doi.org/10.1007/BF00292867
  35. Mangioni C, Bolis G, Pecorelli S, Bragman K, Epis A, Favalli G, Marsoni S. Randomized trial in ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst 81: 1464－1468, 1989 https://doi.org/10.1093/jnci/81.19.1464
  36. Mortine TJ, Borch RF. Quiescent LLC-PK1 cells as a model for cis-diaminedichloro platinum(II) nephrotoxicity and modulation by thio rescue. Cancer Res 48: 24－29, 1988
  37. Mossman T. Rapid colorimatric assay for cellular growth and survival, application and cytotoxic assay. J Immunol Methods 65: 55, 1973 https://doi.org/10.1016/0022-1759(83)90303-4
  38. Prestayko AW, D'Aoust JC, Issell BF, Crook ST. Cisplatin (cis-diamminodichloroplatinum II). Cancer Treat Rev 6: 17－39, 1979 https://doi.org/10.1016/S0305-7372(79)80057-2
  39. Ridgway HJ, Speer RJ, Hall JM. Analogs of sulfato 1,2-diaminocyclohexane platinum(II): Modification in leaving ligand. J Clin Hematol Oncol 7: 220－227, 1977
  40. Rosenberg B, Van Camp L, Grimley EB, Thomson AJ. The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum complexes. J Biol Chem 242: 1347, 1967
  41. Rosenberg B, Van Camp L, Krigas R. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205: 698－699, 1965 https://doi.org/10.1038/205698a0
  42. Rosenberg B, Van Camp L, Trosko JE, Monsour VH. Platinum compound; A new class of potent antitumor agents. Nature 222: 385, 1969 https://doi.org/10.1038/222385a0
  43. Rosenberg B. Platinum complexes-DNA interactions and anticancer activity. Biocheimie 60: 399－406, 1978 https://doi.org/10.1016/S0300-9084(78)80673-7
  44. Rosenberg B. Platinum coordination complexes in cancer chemotherapy. Naturwissenschaften 60: 399－406, 1973 https://doi.org/10.1007/BF00623551
  45. Shimoyama Y, Kubota T, Watanabe M. Predictability of in vivo chemosensitivity by in vitro MTT assay with reference to clonogenic assay. J Surg Oncol 41: 12－18, 1989 https://doi.org/10.1002/jso.2930410107
  46. Vescio RA, Redfen CH, Nelson TJ. In vivo-like drug response of human tumor growing in three dimensional, gel-supported primary culture. Proc Natl Acad Sci 84: 5029－5033, 1987 https://doi.org/10.1073/pnas.84.14.5029
  47. Ward JM, Fauvie KA. The nephrotoxic effects of cis-diaminedichloroplatinum(II) (NSC-119875) in male F344 rats. Toxical Appl Pharmacol 38: 535, 1976 https://doi.org/10.1016/0041-008X(76)90185-X